DUOX1 and lung carcinoma: DUOX1 silencing was also found to promote EGFR TKI resistance and enhance features of CSCs, suggesting the significance of DUOX1 silencing in lung cancer as a possible indicator of lung cancers with poor prognosis or lack of responsiveness to common anticancer therapy.